Frontage offers an impressive suite of services to take lead candidate drugs to the IND stage. With Experimur’s acquisition, Frontage now has significantly expanded our range of services, supporting customers’ drug-development programs beyond IND and into NDA-enabling toxicology studies. Frontage has exceptional bioanalytical supporting capabilities for small molecules, large molecules, and biomarkers.

Performing robust exploratory tests upfront can save time and money later on in the process. This infographic outlines the top reasons for why clients are encouraged to consider a comprehensive exploratory toxicology program and how it can provide success in GLP studies.

In this podcast, we discuss the role of genetic toxicology in drug development.